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SUMMARY

The cholinergic neurons of the basal forebrain (BF)
provide virtually all of the brain’s cortical and amygdalar cholinergic input. They are particularly vulnerable to neuropathology in early Alzheimer’s disease
(AD) and may trigger the emergence of neuropathology in their cortico-amygdalar projection system
through cholinergic denervation and trans-synaptic
spreading of misfolded proteins. We examined
whether longitudinal degeneration within the BF
can explain longitudinal cortico-amygdalar degeneration in older human adults with abnormal cerebrospinal fluid biomarkers of AD neuropathology. We
focused on two BF subregions, which are known to
innervate cortico-amygdalar regions via two distinct
macroscopic cholinergic projections. To further
assess whether structural degeneration of these regions in AD reflects cholinergic denervation, we
used the [18F] FEOBV radiotracer, which binds to cortico-amygdalar cholinergic terminals. We found that
the two BF subregions explain spatially distinct patterns of cortico-amygdalar degeneration, which
closely reflect their cholinergic projections, and overlap with [18F] FEOBV indices of cholinergic denervation.
INTRODUCTION
The emergence of Alzheimer’s disease (AD) neuropathologies,
such as misfolded b-amyloid (Ab) and Tau proteins, progresses
in stages across anatomically and functionally connected regions of the brain, with certain brain regions affected before
others (Braak and Braak, 1991; Braak and Del Tredici, 2015;
Raj et al., 2012, 2015; Seeley et al., 2009). Why certain brain regions appear more vulnerable to AD pathology than others has

long remained a mystery. However, recent functional genomics
research, using brain tissue in both human AD and non-human
animal models of AD, has started to elucidate structural and
functional cell characteristics that predict selective neuronal
vulnerability to AD pathology. Vulnerable neurons typically
have large axonal projections that extend relatively long distances, from one region of the brain to another. As a result,
they require high metabolic expenditure to maintain trophic support—transporting materials over long distances and maintaining enormous cytoskeletal surface areas. These morphological
properties increase vulnerability to oxidative stress and neuroinflammation, perturbed energy homeostasis, and accumulation
of misfolded proteins (Lewis et al., 2010; Mattson and Magnus,
2006; Wang et al., 2010).
The magnocellular cholinergic neurons in the basal forebrain
(BF) are known to have very large projections, targeting distal
areas of the cortical mantle and amygdalae via multiple routes
such as the cingulum bundle (Bloem et al., 2014; Chandler
et al., 2013; Hecker and Mesulam, 1994; Kondo and Zaborszky,
2016; Mesulam et al., 1983a, 1986; Zaborszky et al., 2015). Precise estimates of their size have been difficult to obtain due to
the complexity of their axonal branching. Recently, however,
the complete morphology of individual cholinergic neurons was
visualized in mice using a novel cell labeling technique (Wu
et al., 2014). Extrapolating from their results, the authors
estimated that cholinergic projections in humans approach
100 m in length for a single cell when accounting for all axonal
branches. As a result of their exceptional size, cholinergic neurons are therefore likely to exhibit selective neuronal vulnerability
(SNV) to AD pathology.
Consistent with the SNV model, post-mortem histological evidence suggests that the cholinergic BF neurons accumulate
both intraneuronal Tau, and, interestingly, intraneuronal Ab as
early as the third decade of life, with profound accumulation
observed 1 year after transition to mild cognitive impairment
(MCI) (Arendt et al., 2015; Baker-Nigh et al., 2015; Braak and
Braak, 1991; Braak and Del Tredici, 2015; Geula et al., 2008; Mesulam et al., 2004; Mesulam, 2013; Schliebs and Arendt, 2006,
2011). In vivo neuroimaging data have demonstrated that
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Figure 1. Basal Forebrain Regions of Interest and Longitudinal Degeneration in Early AD
(A) Regions of interest (ROIs) were defined from stereotaxic probabilistic maps of the human basal forebrain (Zaborszky et al., 2008). The nucleus basalis of
Meynert (NbM) is displayed in green. The medial septal nucleus and diagonal band of Broca (MS/DBB) are displayed in red. The ROIs are projected on coronal
slices in standard atlas space (MNI y coordinates are inset).
(B) Longitudinal degeneration (y axis) of both NbM and MS/DBB was elevated among individuals with abnormal cerebrospinal levels of the amyloid-b biomarker
and mild cognitive impairment (AAb MCI) relative to age-matched controls with normal Ab and cognitive function (NAb CN). y axis units are averaged gray matter
volume within each ROI ± SEM.

cognitively normal (CN) older adults expressing abnormal cerebrospinal fluid (CSF) biomarkers of Ab accumulation, i.e., individuals in preclinical stages of AD, exhibit greater longitudinal
degeneration in the BF compared to CN adults with normal
CSF Ab (Schmitz and Spreng, 2016). Furthermore, total gray
matter volume in the BF at baseline was found to predict subsequent longitudinal degeneration in the entorhinal cortex—a
major target of cholinergic innervation (Kondo and Zaborszky,
2016)—and memory impairment. Competing models using
baseline volume in entorhinal cortex to predict longitudinal
degeneration in BF were not supported (Schmitz and Spreng,
2016). These findings suggest a potential interdependence between degeneration in the BF and the cholinoreceptive cortical
targets of its projection system.
Research in non-human animals strongly supports this possibility. In mice bred to express a genetic knockout or knockdown
of the vesicular acetylcholine transporter (VAChT, SLC18A3), a
protein required for acetylcholine (ACh) release from cholinergic
BF neurons (de Castro et al., 2009; Prado et al., 2013), long-term
cholinergic deficiency leads to abnormal accumulation of Ab and
Tau in cholinoreceptive cortical neurons (Kolisnyk et al., 2016,
2017). These data suggest a role for cholinergic signaling in
maintaining normal cell metabolism, including native biological
functions related to the amyloid precursor and Tau proteins. In
parallel to cholinergic denervation, intact but diseased cholinergic inputs might facilitate yet another mechanism of ‘‘seeding’’
the cortex with AD pathology, specifically through the trans-synaptic spread of misfolded Tau fragments (Clavaguera et al.,
2009; de Calignon et al., 2012; Khan et al., 2014).
If the emergence of AD pathology in the cortex is caused by
the loss of cortical cholinergic input or trans-synaptic spreading
of Tau from cholinergic neurons, then the spatial topography
of cortico-amygdalar degeneration should reflect the cholinergic projection system. The cholinergic BF projections exhibit
topographical organization at multiple spatial scales (Ballinger
et al., 2016; Bloem et al., 2014; Kondo and Zaborszky, 2016; Me-

sulam and Geula, 1988; Mesulam et al., 1983b, 1986; Zaborszky
et al., 2015). To accommodate the spatial scale of high-resolution structural magnetic resonance imaging (MRI) data employed
in the present study, we chose a topography that divides the BF
into two segregated macroscopic projections (Zaborszky et al.,
2008), the medial septal nucleus and diagonal band of Broca
(MS/DBB) projection targeting medial temporal lobe, and the
nucleus basalis of Meynert (NbM) projection targeting frontoparietal cortices and the amygdalae (Figures 1A and S1; Experimental Procedures). Structural properties such as gray matter
volume are known to selectively co-vary between brain regions
that are functionally and anatomically connected (AlexanderBloch et al., 2013; Bassett et al., 2008; Cantero et al.,
2017; Chen et al., 2008; Dupre and Spreng, 2017; He et al.,
2007; Kilimann et al., 2017; Schmitz and Spreng, 2016; Spreng
and Turner, 2013), enabling us to test the covariance
in longitudinal structural degeneration between the BF and
distinct targets of its cholinergic projections in the cortex and
amygdalae.
Longitudinal voxel-based morphometry was used to measure
changes in BF and cortico-amygdalar gray matter (GM) volume
over a 2-year interval in older adults with mild cognitive impairment (MCI) and the CSF-Ab biomarker of central AD pathology
(Shaw et al., 2009). These data were acquired from the Alzheimer’s Disease Neuroimaging Initiative (Mueller et al., 2005).
Voxel-based morphometry was used to derive longitudinal
indices of GM degeneration within the BF sub-regions (Grothe
et al., 2018). We then performed a ‘‘seed-to-searchlight’’ analysis to determine whether the BF MS/DBB and NbM sub-regions
(the ‘‘seeds’’) exhibit unique patterns of covariation with regions
of cortex (the ‘‘searchlights’’). We then compared these maps
against a direct in vivo assay of cortical cholinergic denervation
using the positron emission tomography (PET) radiotracer [18F]
FEOBV, which exhibits high binding sensitivity and specificity
to VAChT (Aghourian et al., 2017). We show that in AD, topographies of longitudinal cortical degeneration covary with
Cell Reports 24, 38–46, July 3, 2018 39

Figure 2. Spatial Topography of Covariance between BF and
Cortical Degeneration
Seed-to-searchlight analysis tested whether BF degeneration (averaged over
NbM and MS/DBB sub-regions) covaried with cortical degeneration within
6 mm radius spherical ‘‘searchlight’’ ROIs in the AAb MCI group, controlling for
age, sex, education, total intracranial volume, and longitudinal change in whole
brain volume. Significant searchlights (blue overlay) were determined using a
false discovery rate (FDR)-corrected p < 0.05. Results are projected on an
inflated cortical surface in MNI atlas space.

longitudinal degeneration of the NbM and MS/DBB and closely
reflect the known anatomical organization of the cortical cholinergic projection system, as well as the functional topographies of
cortical cholinergic denervation assayed by [18F] FEOBV PET.
RESULTS
The BF Exhibits Severe Longitudinal Degeneration in
Early AD
To ensure the presence of AD pathology in our sample of older
adults, independent of longitudinal structural MRI, we used the
cerebrospinal fluid amyloid-b biomarker (CSF Ab1–42). Prior analyses of the ADNI core datasets (Shaw et al., 2009) have provided
a cutpoint for CSF Ab1–42 concentration at which diagnostic
sensitivity and specificity to AD is maximal (192 pg mL 1),
yielding correct detection of 96.4% (<192 pg mL 1) and correct
rejection of 95.2% (>192 pg mL 1) (Experimental Procedures).
Only individuals with abnormal CSF Ab1–42 values (AAb) falling
below this cutpoint were included. Second, in order to ensure
our sample was at a stage of AD characterized by longitudinal
degeneration in amygdalar, allocortical, and neocortical areas
(Grothe et al., 2013; Schmitz and Spreng, 2016), we further
filtered individuals according to their neuropsychological status.
Only individuals with a diagnosis of MCI based on the ADNI neuropsychological test battery were included. We included both
MCI individuals who remained stable and converted to AD in
the 2-year study interval. After triangulating AD pathology from
CSF biomarker and neuropsychological measures, our final
sample size of AAb MCI adults was n = 80 (mean ± SD; CSF
Ab1–42 concentration = 136.45 ± 25.31, range = 81–190). See
Table S1 for demographic and neuropsychological information,
as well as CSF total Tau and phosphorylated Tau indices. See
Table S2 for individual ADNI research identifier numbers, sMRI
image identifier numbers, and Ab subgroup designation. Individ40 Cell Reports 24, 38–46, July 3, 2018

uals presenting MCI neuropsychological status but normal CSF
Ab levels were excluded from all forthcoming analyses, as their
cognitive symptoms are likely to be caused by non-AD pathology, for example, vascular dementia and hippocampal sclerosis.
See Table S3 for excluded MCI participants.
We next confirmed that the AAb MCI group exhibited
abnormal longitudinal degeneration in the BF subregional
ROIs: NbM and MS/DBB. To do so, we compared longitudinal
GM changes (time 1 – time 2) in the AAb MCI group against a
control group of age-matched older adults with both normal
CSF Ab1–42 values (NAb) and normal neuropsychological status
(NAb CN: n = 52, mean ± SD; CSF Ab1–42 concentration =
242.46 ± 25.55, range = 196–300). These groups also differed
significantly in their CSF concentrations of total Tau and phosphorylated Tau (Tables S1 and S2). A 2 (group) 3 2 (BF ROI)
repeated-measures ANOVA revealed a significant main effect
of group (F1,130 = 16.4, p < 0.001), driven by significant between
group differences in both BF subregions (NbM: t130 = 3.5, p <
0.001; MS/DBB: t130 = 3.9, p < 0.001) (Figure 1B). We did not
observe a main effect of ROI (F < 1), or a group by ROI interaction
(F = 1). Consistent with existing work on longitudinal structural
degeneration of the BF in MCI (Grothe et al., 2013; Schmitz
and Spreng, 2016), our initial findings indicate that the presence
of AD pathology yielded large increases in the magnitude of
degeneration in both BF nuclei over a 2-year interval compared
to normally aging older adults.
Covariation of Longitudinal Degeneration between the
BF and Cortico-Amygdalar Regions
Having confirmed abnormal BF degeneration in our MCI sample,
we next conducted a regression-based seed-to-searchlight
analysis using the entire BF (NbM and MS/DBB combined) as
the seed region. Searchlight analyses test a statistical model in
small spherical ROIs (‘‘searchlights’’) centered on every voxel,
as opposed to the individual voxels themselves (Kriegeskorte
et al., 2006). At each searchlight, a multiple linear regression
model was performed with mean longitudinal degeneration
(time 1 – time 2) within the BF as the predictor, and nuisance covariates for age, sex, education, total intracranial volume, and
longitudinal change in whole brain volume. The dependent variable was mean degeneration (time 1 – time 2) within the cortical
searchlight. A significant searchlight indicates a covariation in
longitudinal degeneration between the BF and the local neighborhood of voxels within the searchlight region.
Across AAb MCI individuals, we found that larger magnitudes
of longitudinal BF degeneration covaried with larger magnitudes
of cortical degeneration in the frontal, temporal, and parietal
cortices. The data were corrected for multiple comparisons using a false discovery (FDR) rate p < 0.05 (Figure 2). Spatial foci
within these cortical areas are in close agreement with prior
work showing preferential vulnerability to AD pathology in anterior medial temporal cortex, cingulate cortex, and lateral frontoparietal cortices (Buckner et al., 2005). We also observed significant covariation bilaterally in the amygdalae.
We conducted a second seed-to-searchlight analysis in the
NAb CN group, using the same model specifications as in
the AAb MCI group. However, this model failed to detect suprathreshold cortical degeneration after correction for multiple

Figure 3. Degeneration within BF NbM and
MS/DBB Nuclei Covaries with Distinct
Spatial Topographies of Degeneration in
Their Cortical Targets
Seed-to-searchlight analysis tested whether the
NbM or MS/DBB BF subregions selectively covaried with cortical degeneration in the AAb
MCI group, controlling for degeneration in the
opposing BF subregion (MS/DBB and NbM,
respectively). The NbM selectively covaried with
degeneration (green overlays) in distributed areas
of frontal, parietal, and occipital cortex (top), as
well as in the amygdalae (bottom). The MS/DBB
selectively covaried with degeneration (red overlays) in more circumscribed areas of temporal
cortex including the middle temporal gyrus
(cortical surfaces), and the entorhinal cortices
(bottom). Additional areas included the temporoparietal and left inferior frontal cortices. Significant
searchlights were determined using a FDR-corrected p < 0.05. Top: results are projected on an
inflated cortical surface in MNI atlas space. Bottom: results are displayed on coronal slices in MNI
atlas space (y coordinates are inset).

comparisons. Hence, these patterns do not appear to reflect
normal age-related patterns of covariance between BF and
cortical degeneration.
Cortico-Amygdalar Covariation with BF Subregions
Reflects the Cholinergic BF Projections
Many of the spatial foci identified by this initial analysis are also
known to be strongly innervated by the ascending cholinergic
projections, including the entorhinal cortex, hippocampus,
amygdalae, and medial prefrontal cortex (Bloem et al., 2014;
Chandler et al., 2013; Hecker and Mesulam, 1994; Kondo and
Zaborszky, 2016; Mesulam et al., 1986, 1983a; Zaborszky
et al., 2015). However, the observed spatial topography may
merely reflect coincidental degeneration of the BF, cortex, and
amygdalae; AAb MCI individuals with larger magnitudes of BF
degeneration may tend to exhibit larger magnitudes of corticoamygdalar degeneration due to parallel independent events. If
this were the case, we would not expect degeneration within
subregions of the BF to exhibit distinct patterns of covariation
with degeneration in the cortex and amygdalae. Alternatively, if
pathological events within the cholinergic BF subregions and
their cortico-amygdalar targets are linked, longitudinal degeneration in NbM and MS/DBB should exhibit a pattern of corticoamygdalar interdependence reflecting the distinct topography
of their projections.
To adjudicate these competing alternatives, we conducted
two modified seed-to-searchlight analyses on each BF subre-

gion—NbM and MS/DBB—that are
known to form segregated macroscopic
projections to distinct areas of cortex
and amygdalae. Each analysis examined
whether mean longitudinal degeneration
(time 1 – time 2) within either the NbM or
MS/DBB ROI selectively covaried with
mean degeneration within the cortical searchlights, while controlling for degeneration in the opposing subregion. As before,
additional covariates included age, sex, education, total intracranial volume, and longitudinal change in whole brain volume.
Across AAb MCI individuals, we observed that NbM and MS/
DBB selectively covaried with distinct topographies of cortical
degeneration that closely align with the segregated organization
of their cholinergic projections (Figure 3). Higher magnitudes of
NbM degeneration selectively covaried with higher magnitudes
of degeneration in a more distributed topography reflecting its
widespread cholinergic innervations of the frontal, parietal, and
occipital cortices (Bloem et al., 2014; Mesulam and Geula,
1988; Mesulam et al., 1986, 1983a). The NbM also selectively
covaried with higher focal degeneration in the amygdalae, an
area which is densely innervated by its cholinergic projections
(Hecker and Mesulam, 1994).
By contrast, the MS/DBB selectively covaried with higher
magnitudes of degeneration in a more circumscribed topography. Degeneration within the temporal lobe, including the entorhinal cortex and extending laterally into the middle temporal
gyri, are areas known to receive cholinergic innervations from
the medial septal nucleus (MS) and vertical band of the DBB
(Kondo and Zaborszky, 2016). Areas of MS/DBB covariation
outside of the temporal cortex included the olfactory cortex,
an area known to receive cholinergic projections from the horizontal band of the DBB (Mesulam et al., 1983a, 1986). Our
longitudinal findings are consistent with cross-sectional studies
Cell Reports 24, 38–46, July 3, 2018 41

Figure 4. Spatial Convergence across Multimodal Indices of Cortical Cholinergic Degeneration
(A) A map of cortical cholinergic degeneration assayed by between group comparison of [18F] FEOBV binding in cognitively normal versus AD adults (primary
cluster forming threshold p uncorrected <0.001, secondary FDR cluster level threshold <0.05).
(B) A composite of the seed-to-searchlight maps for each BF subregion (Figure 3) was generated using a logical OR operation.
(C) A conjunction analysis (logical AND) was then applied to the FDR-corrected maps in (A) and (B). Results are projected on an inflated cortical surface in MNI
atlas space.

demonstrating stronger inter-regional covariation of MS/DBB
with hippocampal and amygdalar gray matter, and NbM with
cingulate gray matter, in MCI compared to CN older adults (Cantero et al., 2017; Kilimann et al., 2017).
The subregional NbM and MS/DBB searchlight topographies
were more spatially restricted than the searchlight topography
observed in the initial analysis (both NbM and MS/DBB combined; Figure 2), especially in the cortical midline, indicating
that the NbM and MS/DBB share common variance in these
searchlight locations.
Convergent Structural and Functional Topographies of
Cholinergic Degeneration
Our seed-to-searchlight structural degeneration maps suggest
an interdependence between AD pathology within the BF projection system and its cortico-amygdalar targets. However, by itself, sMRI cannot determine whether the observed structural interdependencies (Figure 3) are specific to cortical cholinergic
innervations. We therefore adopted a multimodal imaging strategy using the [18F] FEOBV PET radiotracer, which exhibits a very
high binding affinity and an excellent specificity for the vesicular
acetylcholine transporter (VAChT), a glycoprotein found on the
membrane of synaptic vesicles of cholinergic neurons (Aghourian et al., 2017; Cyr et al., 2014; Parent et al., 2012) (Figure S2;
Table S4; Supplemental Experimental Procedures). The [18F]
FEOBV tracer provides an estimate of presynaptic neuronal
42 Cell Reports 24, 38–46, July 3, 2018

integrity and is thought to remain unaffected by the post-synaptic activity of enzymes such as acetylcholinesterase (ACHE),
although this has yet to be demonstrated in vivo. Cortical cholinergic denervation, whether induced experimentally via selective
lesions of the BF nuclei in rats (Cyr et al., 2014; Parent et al.,
2012), or due to AD pathology in humans (Aghourian et al.,
2017), both alter regionally specific patterns of [18F] FEOBV
binding.
We first compared cognitively normal (n = 6) and AD (n = 6)
older adults with indices of [18F] FEOBV PET, collected as part
of a prior study (Aghourian et al., 2017), to identify areas of significant cholinergic denervation. A two-sample t test controlling for
age (Table S4; Experimental Procedures) revealed lower [18F]
FEOBV binding in the AD group spanning lateral fronto-parietal
and temporal cortical areas. Due to the smaller sample sizes,
we first imposed a cluster-forming threshold with an uncorrected
p < 0.001, followed a cluster-level FDR-corrected p < 0.05 (Woo
et al., 2014) (Figure 4A). We note that no differences were
observed in the thalamus, medial temporal lobe, or amygdalar
areas at the FDR-corrected threshold.
We next examined the precise areas of spatial convergence
between the [18F] FEOBV assay of cholinergic denervation (Figure 4A) and our seed-to-searchlight assay of BF-dependent
structural degeneration (Figure 4B). To do so, a logical AND
operation was performed on the FDR-corrected maps from
each imaging modality (Nichols et al., 2005). The resulting

conjunction revealed tight correspondence in virtually all cortical
areas of the left hemisphere. The right hemisphere exhibited
lower spatial overlap, due in part to weaker effect sizes of clusters in these areas in the [18F] FEOBV group comparison (Figure 4C). Taken together, these findings indicate that spatial
topographies of cortical degeneration in AD reflect the anatomical topography of the cholinergic projection system, and thus
suggest the loss of cortical cholinergic input from the BF might
play a major role in the emergence of cortico-amygdalar gray
matter degeneration.
DISCUSSION
We demonstrated that the MS/DBB and NbM subregions of the
basal forebrain covary with segregated topographies of cortical
degeneration (Figure 3). These topographies align closely with
the known anatomical segregation between the cholinergic projections of the MS/DBB and NbM subregions (Bloem et al., 2014;
Hecker and Mesulam, 1994; Kondo and Zaborszky, 2016; Mesulam et al., 1983a, 1986; Zaborszky et al., 2015). We then used
[18F] FEOBV PET indices of binding with the vesicular acetylcholine transporter (VAChT) to demonstrate that cortical cholinergic
denervation in AD exhibits spatial correspondence with our
BF-dependent structural degeneration maps (Figure 4).
If the cholinergic BF neurons are selectively vulnerable to perturbed energy homeostasis, oxidative stress, and neuroinflammation due to their large axons (Lewis et al., 2010; Mattson
and Magnus, 2006; Wang et al., 2010; Wu et al., 2014), they
might lose the capacity to maintain full trophic support of these
large axons over the course of aging. Lending support to this hypothesis, the number of cholinergic fibers per BF neuron reduces
in early middle age, and especially in the transition from preclinical to MCI stages of AD, against a background of accumulating
intraneuronal Ab, hyper-phosphorylated Tau, and neurofibrillary
tangles (Arendt et al., 2015; Baker-Nigh et al., 2015; Braak and
Braak, 1991; Braak and Del Tredici, 2015; Geula et al., 2008; Mesulam et al., 2004; Mesulam, 2013; Schliebs and Arendt, 2006,
2011). As a result, the cortex and amygdalae might become progressively denuded of cholinergic input, with genetic AD risk factors such as the APOE ε4 allele (Poirier et al., 1995) and reduced
metabolism (Rivera et al., 2005) contributing to differentiate
normal age-related from AD trajectories of cholinergic loss.
Work in non-human animals indicates that cortico-amygdalar
cholinergic denervation is a pivotal event in the AD pathophysiological cascade. Among mice bred to express a deficiency in
VAChT (SLC18A3) capacity, the consequent reduction in cholinergic tone across the lifespan is, by itself, sufficient to induce aggregation of Ab and hyper-phosphorylated Tau within brain
areas receiving BF cholinergic projections, such as the hippocampus (Kolisnyk et al., 2016, 2017). Under this scenario, loss
of cholinergic BF projections might ‘‘seed’’ pathophysiological
changes in their cortical and amygdalar targets due to loss of
cholinergic signaling. In parallel to the loss of cholinergic input,
intact but diseased cholinergic projections might also transmit
Tau trans-synaptically to cholinoreceptvie cortico-amygdalar
neurons. Trans-synaptic spread of Tau has been reported
for glutamatergic neurons in the entorhinal and hippocampal
cortices (Clavaguera et al., 2009; de Calignon et al., 2012;

Khan et al., 2014), however, the findings imply a general mechanism by which AD pathology can spread from diseased neurons
to functionally and anatomically connected healthy neurons. In
either scenario, degeneration within cortico-amygdalar targets
of cholinergic BF projections should reflect the topography of
the cholinergic projections themselves. We provide additional
support for this hypothesis with longitudinal structural MRI.
In humans, cholinergic hypofunction correlates with the formation of Ab plaques, tangles containing hyper-phosphorylated
Tau and clinical severity of AD (Auld et al., 2002; Fisher, 2012).
We observed that in addition to abnormal CSF Ab concentration
(that was used as a grouping variable), both CSF phosphorylated
Tau and total Tau were significantly elevated in the AAb MCI
compared to the NAb CN group (Table S1). Although we cannot
infer from CSF data where and how these biomarkers are distributed in the brain, our findings demonstrate that in the MCI group
longitudinal gray matter degeneration within the cortico-amygdalar cholinergic BF projection system, as well as cognitive
decline, occurred against a biomolecular background of significant neuropathology. Nevertheless, in humans, stronger connections are needed to link the progression of cortical cholinergic denervation to its potentially very early roles in driving
cortical neuropathology and altering cortical functions important
for cognition, such as selective attention (Romberg et al., 2013;
Schmitz et al., 2010, 2014; Schmitz and Duncan, 2018).
Standard T1-weighted sMRI measures of gray matter volume
cannot distinguish different cell types. Hence, we cannot infer
from our sMRI data alone whether longitudinal reductions in
gray matter within the BF reflect a selective loss of cholinergic
cell bodies, or some combination of cholinergic, GABAergic,
and glutamatergic neurons known to co-populate its MS/DBB
and NbM subregions (Henny and Jones, 2008; Lin et al., 2015).
The [18F] FEOBV PET radiotracer obviates this limitation. Unlike
FDG and amyloid radiotracers, [18F] FEOBV provides a highly
sensitive and selective biomarker of central cholinergic integrity—VAChT binding (Aghourian et al., 2017). In the present
study, we did not have access to longitudinal structural MRI
and [18F] FEOBV PET within the same individuals. Although we
assessed the spatial convergence between imaging modalities
using conjunction analysis in MNI template space, the accuracy
of co-registration between modalities can be further improved by
acquiring high-resolution PET and structural MRI within the same
individuals. Finally, we note that [18F] FEOBV PET was acquired
in AD participants who were actively taking ACHE inhibitors to
treat cognitive symptoms. Systematic investigation is required
to determine whether these drugs might influence [18F] FEOBV
binding.
Future work will benefit from a within-subjects multimodal
imaging strategy combining longitudinal [18F] FEOBV PET with
structural MRI, as well as direct evaluation of how pharmacological intervention with ACHE inhibitors influences these measures.
Nevertheless, our present findings underscore the need for
in vivo measures of cell-type-specific degeneration of the cholinergic system. Longitudinal monitoring of [18F] FEOBV binding in
cohorts of cognitively normal APOE ε4 carriers and non-carriers,
in combination with CSF biomarker indices of neuropathology,
will provide novel insights into the differential trajectories of the
neurotypical and preclinical aging brain.
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EXPERIMENTAL PROCEDURES
Structural MRI
Data used in the preparation of this article were obtained from the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) database (http://adni.loni.usc.edu).
The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner, MD. The primary goal of ADNI has
been to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), cerebrospinal fluid (CSF) biomarkers, and clinical and
neuropsychological assessment can be combined to measure the progression
of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD).
Methodological steps for group classification (cognitively normal and early
AD), structural MRI preprocessing, and definition of basal forebrain ROIs are
in the Supplemental Information.
Seed-to-Searchlight Analyses
Longitudinal differences in GM were computed for the combined BF (NbM,
MS/DBB) ROI and the NbM and MS/DBB sub-region ROIs, for each subject.
These values were entered into multiple linear regression models (either combined BF only, or both NbM and MD/DBB) as the predictor ‘‘seeds.’’ In both
cases, additional covariates included: age, sex, education, total intracranial
volume, and longitudinal change in whole brain volume. The dependent measure was the longitudinal difference in GM within a 6-mm radius spherical
searchlight ROI. Over successive iterations, the searchlight was positioned
at every voxel constrained within the population-average gray matter mask,
producing a seed-to-searchlight map. At each searchlight the multiple linear
regression was computed with the robust fitting method (i.e., robust regression) (Wilcox, 2004) to reduce potential outlier effects. Code for the seed-tosearchlight analyses was adapted from the freely available RSA Toolbox (Nili
et al., 2014). Statistical significance on the searchlight maps was determined
at a FDR-corrected p < 0.05.
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[F] FEOBV PET
The [18F] FEOBV PET radiotracer was acquired in 12 participants: six patients
diagnosed with probable AD and six age-matched healthy volunteers (Table
S4). These sample sizes are similar to those of previous rodent studies
comparing FEOBV binding between an experimental group with induced
mild cholinergic lesions and controls (Cyr et al., 2014; Parent et al., 2012). All
participants were recruited at the McGill Centre for Studies in Aging (MCSA)
and assessed at the McConnell Brain Imaging Unit (BIC) of the Montreal
Neurological Institute (MNI). The original study protocol was approved by ‘‘Université du Québec à Montréal’’ (UQAM), and McGill University Research Ethics
Boards. Informed consent was obtained from all subjects prior to participation
in the study.
Methodological steps for group classification (cognitively normal and early
AD) and [18F] FEOBV PET preprocessing are in the Supplemental Information.
ANCOVA Model
We used SPM12 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12/) to
conduct a between groups analysis (CN versus AD). The parameters for the
general linear model specification were as follows: threshold masking = relative (0.8), global calculation = mean voxel value, global normalization = overall
grand mean scaling (50); normalization = ANCOVA. Other parameter fields
were set to default values. Age was modeled as a covariate of non-interest
in the model. Statistical significance on the between group contrast (CN >
AD) was determined at a cluster-level FDR-corrected p < 0.05.
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